Metformin and survival in pancreatic cancer: a retrospective cohort study
- PMID: 24051965
- PMCID: PMC3779343
- DOI: 10.1097/MPA.0b013e3182965a3c
Metformin and survival in pancreatic cancer: a retrospective cohort study
Abstract
Objectives: Our aim was to determine the effect of metformin exposure on survival in patients with advanced pancreatic adenocarcinoma (PAC).
Methods: A retrospective cohort study was conducted using The Health Improvement Network, a primary care electronic medical record database from the United Kingdom (2003-2010). The study cohort included all subjects with a diagnostic code for incident PAC and a preexisting diagnosis of type 2 diabetes mellitus. Subjects were classified as exposed if they were prescribed metformin around the time of PAC diagnosis (between 6 months prior and 1 month after). A secondary analysis was performed only on exposed subjects without prior (ie, 6 months before PAC diagnosis) exposure to metformin. The primary outcome was overall survival. The analysis was performed using univariate and multivariable Cox proportional hazards models.
Results: The study included 516 subjects with preexisting type 2 diabetes mellitus and PAC, 247 of which were exposed to metformin. In univariate and multivariable analysis, there was no difference in survival between those exposed and those unexposed to metformin in the primary analysis (hazards ratio, 1.11 [0.89-1.38], P = 0.367) or the secondary analysis (hazards ratio, 1.09 [0.80-1.47], P = 0.585).
Conclusions: Metformin use is not associated with improved survival in subjects with advanced PAC.
Conflict of interest statement
There are no financial disclosures or conflicts of interest.
Figures
Similar articles
-
Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis.Oncotarget. 2017 Apr 11;8(15):25242-25250. doi: 10.18632/oncotarget.15692. Oncotarget. 2017. PMID: 28445955 Free PMC article. Review.
-
Type 2 diabetes mellitus and survival in pancreatic adenocarcinoma: a retrospective cohort study.Cancer. 2013 Jan 15;119(2):404-10. doi: 10.1002/cncr.27731. Epub 2012 Aug 1. Cancer. 2013. PMID: 23292900
-
Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2.Dig Liver Dis. 2016 Apr;48(4):435-40. doi: 10.1016/j.dld.2015.12.006. Epub 2015 Dec 21. Dig Liver Dis. 2016. PMID: 26775128
-
Metformin use is associated with better survival of diabetic patients with pancreatic cancer.Clin Cancer Res. 2012 May 15;18(10):2905-12. doi: 10.1158/1078-0432.CCR-11-2994. Epub 2012 Mar 31. Clin Cancer Res. 2012. PMID: 22465831 Free PMC article.
-
Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis.Medicine (Baltimore). 2018 Jul;97(30):e11596. doi: 10.1097/MD.0000000000011596. Medicine (Baltimore). 2018. PMID: 30045293 Free PMC article. Review.
Cited by
-
The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer.Gut Liver. 2016 Sep 15;10(5):665-71. doi: 10.5009/gnl15451. Gut Liver. 2016. PMID: 27563018 Free PMC article. Review.
-
Diabetes and cancer: Associations, mechanisms, and implications for medical practice.World J Diabetes. 2014 Jun 15;5(3):372-80. doi: 10.4239/wjd.v5.i3.372. World J Diabetes. 2014. PMID: 24936258 Free PMC article. Review.
-
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future.J Hematol Oncol. 2015 May 3;8:44. doi: 10.1186/s13045-015-0141-5. J Hematol Oncol. 2015. PMID: 25935754 Free PMC article. Review.
-
Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis.Am J Gastroenterol. 2016 Sep;111(9):1350-7. doi: 10.1038/ajg.2016.288. Epub 2016 Jul 19. Am J Gastroenterol. 2016. PMID: 27430290 Free PMC article.
-
Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis.Oncotarget. 2017 Apr 11;8(15):25242-25250. doi: 10.18632/oncotarget.15692. Oncotarget. 2017. PMID: 28445955 Free PMC article. Review.
References
-
- Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. - PubMed
-
- Howlader NNA, Krapcho M, Neyman N, et al. SEER Cancer Statistics Review. National Cancer Institute; Bethesda, MD: 1975–2008.
-
- Jimenez RE, Fernandez-del Castillo C. Pancreatic Cancer. 9. 2010.
-
- Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27(33):5513–5518. - PubMed
-
- Scheithauer W, Schull B, Ulrich-Pur H, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol. 2003;14(1):97–104. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical